In a human activated T cell and T cell ALL model, PARP inhibitors were found to antagonize NAD depletion and increase NAD levels, thus antagonizing NAMPTi-induced NAD depletion and its downstream effects (43). The gene discussed is PARP1; the disease is acute lymphoblastic leukemia.